Kollias-Baker C, Xu J, Pelleg A, Belardinelli L
Department of Medicine, University of Florida, Gainesville 32610.
Circ Res. 1994 Dec;75(6):972-80. doi: 10.1161/01.res.75.6.972.
The 2-amino-3-benzoylthiophene derivative PD 81,723 potentiates the A1 receptor-mediated negative dromotropic effect of exogenous adenosine and adenosine receptor agonists in guinea pig isolated perfused and in situ hearts. The objective of this study was to determine whether PD 81,723 could amplify the cardiac actions of endogenous adenosine. Two approaches known to increase the myocardial interstitial concentration of adenosine--hypoxia, which increases the production of adenosine and the inhibition of adenosine kinase, which decreases its metabolism--were used to test this hypothesis. In guinea pig hearts in situ, PD 81,723 (2 mg/kg i.v.) potentiated the atrioventricular (AV) nodal conduction delay caused by hypoxemia (PaO2, 14 to 19 mm Hg). In guinea pig isolated hearts, PD 81,723 (5 mumol/L) increased by twofold the stimulus-to-His bundle (S-H) interval prolongations induced by both a 5-minute period of hypoxia (25% O2/70% N2/5% CO2) and the administration of the adenosine kinase inhibitor iodotubercidin (40 to 70 nmol/L) but had no effect on coronary conductance. Hypoxia and hypoxia plus PD 81,723 (5 mumol/L) caused equivalent increases in the concentration of adenosine in epicardial transudate, from 0.13 +/- 0.15 to 0.48 +/- 0.1 and 0.45 +/- 0.4 mumol/L, respectively. Similar to the allosteric enhancer, the nucleoside uptake blocker draflazine (0.1 mumol/L) also increased by twofold the S-H interval prolongation caused by hypoxia. In contrast to the allosteric enhancer, draflazine increased the concentration of adenosine in epicardial transudate during hypoxia from 0.48 +/- 0.15 to 1.5 +/- 0.4 mumol/L. Draflazine also increased coronary conductance by approximately twofold in guinea pig normoxic constant-fold perfused hearts.(ABSTRACT TRUNCATED AT 250 WORDS)
2-氨基-3-苯甲酰基噻吩衍生物PD 81,723可增强豚鼠离体灌注心脏和原位心脏中外源性腺苷及腺苷受体激动剂由A1受体介导的负性变传导作用。本研究的目的是确定PD 81,723是否能增强内源性腺苷的心脏作用。采用两种已知可增加心肌间质腺苷浓度的方法——缺氧(可增加腺苷生成)和抑制腺苷激酶(可减少其代谢)来验证这一假设。在豚鼠原位心脏中,PD 81,723(静脉注射2mg/kg)可增强低氧血症(动脉血氧分压,14至19mmHg)所致的房室(AV)结传导延迟。在豚鼠离体心脏中,PD 81,723(5μmol/L)可使由5分钟缺氧(25%氧气/70%氮气/5%二氧化碳)和给予腺苷激酶抑制剂碘结核菌素(40至70nmol/L)所诱导的刺激至希氏束(S-H)间期延长增加两倍,但对冠脉传导无影响。缺氧以及缺氧加PD 81,723(5μmol/L)分别使心外膜渗出液中腺苷浓度从0.13±0.15增加至0.48±0.1和0.45±0.4μmol/L,增幅相当。与变构增强剂类似,核苷摄取阻滞剂draflazine(0.1μmol/L)也可使缺氧所致的S-H间期延长增加两倍。与变构增强剂不同的是,draflazine可使缺氧时心外膜渗出液中腺苷浓度从0.48±0.15增加至1.5±0.4μmol/L。在豚鼠常氧恒流灌注心脏中,draflazine还可使冠脉传导增加约两倍。(摘要截选至250词)